Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
1.
Clin Transl Oncol ; 22(4): 585-602, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31256361

ABSTRACT

PURPOSE: To determine whether cytomegalovirus is causally associated with breast cancer and whether cytomegalovirus should be categorised as an oncogenic virus. METHODS: We undertook a review of published epidemiological and laboratory studies, using established causal criteria: Bradford Hill criteria to determine whether cytomegalovirus is associated with breast cancer; and Evans/Mueller criteria to determine whether cytomegalovirus should be categorised as an oncogenic virus. RESULTS: Although there are inconsistencies in the findings of published epidemiological and laboratory studies, these may be explained by factors such as: differences in timing of blood samples, differences in selection of cases and controls, or high cytomegalovirus seroprevalence among participants in the epidemiological studies; and, in the laboratory studies, differences in sample preparations, age of sample, whether or not paired breast cancer and normal breast tissue samples were used, differences in the tests, primers and/or antibodies used, differences in histological types of breast cancer studied, and/or features of the virus. CONCLUSIONS: Overall, the results of published studies of cytomegalovirus and breast cancer suggest cytomegalovirus is a causal factor for at least some types of breast cancer. If the evidence for a link between cytomegalovirus and breast cancer continues to strengthen, further research could lead to: targeted screening; therapy using antiviral drugs; and, perhaps, primary prevention of a significant proportion of breast cancer. Vaccination against viruses has already been shown to be effective in preventing cervix and liver cancer; cytomegalovirus vaccines are already under development.


Subject(s)
Breast Neoplasms/virology , Cytomegalovirus/isolation & purification , Animals , Breast Neoplasms/etiology , Cytomegalovirus/genetics , Cytomegalovirus/immunology , Female , Humans , Mice
2.
N Z Vet J ; 67(6): 329-332, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31378159

ABSTRACT

Aims: To determine if presence of the Bacteroides fragilis toxin (bft) gene, a molecular marker of colonic carriage of entertoxigenic Bacteroides fragilis (ETBF) in humans, was associated with a finding of small intestinal adenocarcinomas (SIA) in sheep in New Zealand. Methods: Samples of jejunal tissue were collected from the site of tumours and from grossly normal adjacent tissue in 20 sheep, in different consignments, diagnosed with SIA based on gross examination of viscera following slaughter. Two jejunal samples were also collected from a control sheep in the same consignment that had no gross evidence of SIA. A PCR assay was used to detect the presence of the bft gene in the samples. Results: Of the sheep with SIA, the bft gene was amplified from one or both samples from 7/20 (35%) sheep, and in sheep that had no gross evidence of SIA the bft gene was amplified from at least one sample in 11/20 (55%) sheep (RR 0.61; 95% CI = 0.30-1.25; p = 0.34). Of 11 positive samples analysed, ETBF subtype bft-1 was detected in one, bft-2 was detected in 10, and none were bft-3. Conclusions and Clinical Relevance: There was a high prevalence of detection of the bft gene in both SIA-affected and non-affected sheep, but there was no apparent association between carriage of ETBF, evidenced by detection of the bft gene, and the presence of SIA. ETBF are increasingly implicated in the aetiology of human colorectal cancer, raising the possibility that sheep may provide a zoonotic reservoir of this potentially carcinogenic bacterium. Abbreviation: Bft: Bacteroides fragilis toxin; ETBF: Enterotoxigenic Bacteroides fragilis; SIA: Small intestinal adenocarcinoma.


Subject(s)
Adenocarcinoma/veterinary , Bacterial Toxins/genetics , Intestinal Neoplasms/veterinary , Metalloendopeptidases/genetics , Sheep Diseases/diagnosis , Adenocarcinoma/diagnosis , Adenocarcinoma/microbiology , Animals , Bacterial Toxins/isolation & purification , DNA, Bacterial/analysis , Genes, Bacterial , Intestinal Neoplasms/diagnosis , Intestinal Neoplasms/microbiology , Metalloendopeptidases/isolation & purification , Sheep , Sheep Diseases/microbiology
3.
Rev Sci Instrum ; 90(12): 124502, 2019 Dec 01.
Article in English | MEDLINE | ID: mdl-31893794

ABSTRACT

Micropore optics have recently been implemented in a lobster eye geometry as a compact X-ray telescope. Fields generated by rare-earth magnets are used to reduce the flux of energetic electrons incident upon the focal plane detector in such a setup. We present the design and implementation of the electron diverters for X-ray telescopes of two upcoming missions: the microchannel X-ray telescope onboard the space-based multiband astronomical variable objects monitor and the soft X-ray instrument onboard the solar wind magnetosphere ionosphere link explorer. Electron diverters must be configured to conform to stringent limits on their total magnetic dipole moment and be compensated for any net moment arising from manufacturing errors. The two missions have differing designs, which are presented and evaluated in terms of the fractions of electrons reaching the detector, as determined by relativistic calculations of electron trajectories. The differential flux of electrons to the detector is calculated, and the integrated electron background is determined for both designs.

4.
Parkinsonism Relat Disord ; 42: 78-84, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28693940

ABSTRACT

BACKGROUND: Traditionally the risk of Parkinson's has been considered to increase monotonically with age, although there is evidence that prevalence and incidence may decrease in the oldest old. To examine this further we estimated the national prevalence and incidence of Parkinson's in New Zealand, using drug-tracing methods, to examine the relationship of Parkinson's with sex and age up to 100+. METHODS: Information on Parkinson's-related medications was extracted from the national pharmaceutical database of community-dispensed medications from 2005 to 2014. Diagnoses for a large subset of individuals were independently determined through national mortality and hospital admissions datasets. We used a Bayesian model, accommodating diagnostic uncertainty and bias, to estimate the number of people with Parkinson's. RESULTS: The 2013 prevalence of Parkinson's in New Zealand was 210 per 100 000 population (95% uncertainty interval 208-212) with age-standardized prevalence rates higher for males (ratio 1.6:1). Incidence was 31 per 100 000 person-years (95% uncertainty interval 30-32), also higher in males (ratio 1.8:1). Incidence and prevalence by age increased exponentially until 75 years, peaked at 85 years, and then dropped sharply. CONCLUSIONS: The prevalence of Parkinson's in New Zealand is expected to double over a 25-year period but then increase at a slower rate due to the drop-off in prevalence and incidence in the oldest old. The findings suggest that Parkinson's disease is not an aging-dependent but an age-dependent disorder.


Subject(s)
Aging , Parkinson Disease/economics , Parkinson Disease/epidemiology , Aged, 80 and over , Algorithms , Cost of Illness , Female , Humans , Incidence , Longitudinal Studies , Male , New Zealand/epidemiology , Parkinson Disease/classification , Prevalence , Residence Characteristics , Retrospective Studies
5.
Acta Neurol Scand ; 136(3): 223-232, 2017 Sep.
Article in English | MEDLINE | ID: mdl-27891575

ABSTRACT

BACKGROUND AND OBJECTIVES: We investigated the demographic, social and clinical characteristics associated with employment status and income for people with multiple sclerosis (MS) in New Zealand (NZ). METHODS: The NZ National MS Prevalence study included all persons resident in NZ on census day 2006 diagnosed with MS (96.7% coverage). Factors associated with employment and income status among the working age population (25-64 years) were identified by linear regression. RESULTS: Over 90% of working age people with MS (n=1727) had a work history, but 54% were not working. Work loss occurred early in the disease course, and at low disability (P<.001). Advancing age, progressive disease, longer disease duration, higher disability levels, partner loss and lower education were associated with work loss (P<.001). Working age people with MS had lower income than the NZ population (P<.0001). Higher qualifications yielded no additional income for MS females and about half the additional income for MS males (P<.0001). CONCLUSIONS: MS profoundly reduces employment and income early in the disease course, and at low levels of disability, however, unemployment is not entirely accounted for by clinical, social and demographic factors. These findings suggest social supports should be explored early in the disease course to reduce loss of income and unemployment for people with MS.


Subject(s)
Employment/statistics & numerical data , Income/statistics & numerical data , Multiple Sclerosis/epidemiology , Adult , Female , Humans , Male , Middle Aged , Multiple Sclerosis/economics , New Zealand
6.
Intern Med J ; 46(12): 1414-1421, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27664975

ABSTRACT

BACKGROUND: Chronic lymphocytic leukaemia (CLL) is associated with an increased incidence and aggressiveness of skin cancers, particularly cutaneous squamous cell carcinoma (cSCC), but little is known about cSCC incidence in Australasian CLL patients. AIM: In this retrospective study, we analysed the incidence of cSCC in patients seen at a tertiary hospital in New Zealand (NZ). METHODS: We retrospectively assessed the clinical history and histology data of CLL patients (n = 371) who presented to the Haematology Department, Christchurch Hospital, NZ during the period 1996-2015. Baseline characteristics, incidence of second cancers, treatment details and overall survival were analysed. RESULTS: During follow-up (median = 11.8 years), 221 second cancers were recorded in 88 patients. Of these cancers, 185 were cSCC, removed from 61 patients. In 56% of these patients, >1 cSCC was removed, and the majority of cSCC occurred following the treatment for CLL. The cumulative incidence of a first cSCC was 11% at 5 years, whereas the cumulative incidence of a subsequent cSCC was 88% at 5 years. The incidence of cSCC in male patients was threefold higher than that reported for the general NZ population. CONCLUSION: NZ CLL patients have a high incidence of cSCC relative to the levels observed in the general population, which are themselves among the highest in the world. The careful monitoring of CLL patients is warranted, particularly those who have a progressive disease or have had a first cSCC removed.


Subject(s)
Carcinoma, Squamous Cell/epidemiology , Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology , Neoplasms, Second Primary/epidemiology , Skin Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Female , Follow-Up Studies , Humans , Incidence , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Male , Middle Aged , Neoplasm Recurrence, Local , Neoplasms, Second Primary/pathology , Neoplasms, Second Primary/therapy , New Zealand/epidemiology , Retrospective Studies , Skin Neoplasms/pathology , Skin Neoplasms/therapy
7.
Intern Med J ; 42(11): 1207-12, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22373014

ABSTRACT

BACKGROUND: Identifying eligible individuals for a prevalence survey is difficult in the absence of a disease register or a national population register. AIM: To develop a method to identify and invite eligible individuals to participate in a national prevalence survey while maintaining confidentiality and complying with privacy legislation. METHODS: A unique identifier (based on date of birth, sex and initials) was developed so that database holders could identify eligible individuals, notify us and invite them on our behalf to participate in a national multiple sclerosis prevalence survey while maintaining confidentiality and complying with privacy legislation. RESULTS: Several organisations (including central government, health and non-governmental organisations) used the method described to assign unique identifiers to individuals listed on their databases and to forward invitations and consent forms to them. The use of a unique identifier allowed us to recognise and record all the sources of identification for each individual. This prevented double counting or approaching the same individual more than once and facilitated the use of capture-recapture methods to improve the prevalence estimate. Capture-recapture analysis estimated that the method identified over 96% of eligible individuals in this prevalence survey. CONCLUSIONS: This method was developed and used successfully in a national prevalence survey of multiple sclerosis in New Zealand. The method may be useful for prevalence surveys of other diseases in New Zealand and for prevalence surveys in other countries with similar privacy legislation and lack of disease registers and population registers.


Subject(s)
Cross-Sectional Studies/methods , Health Surveys/methods , Patient Identification Systems/methods , Confidentiality/legislation & jurisprudence , Cross-Sectional Studies/ethics , Databases, Factual , Health Surveys/ethics , Humans , Medical Records , Multiple Sclerosis/epidemiology , New Zealand/epidemiology , Patient Identification Systems/ethics , Prevalence , Privacy , Surveys and Questionnaires
8.
J Affect Disord ; 126(1-2): 140-6, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20381156

ABSTRACT

BACKGROUND: Cloninger's Temperament and Character Inventory (TCI) is a widely used measure of personality. Two scales of the TCI, harm avoidance (HA) and self directedness (SD), have been shown to be influenced by depressed mood. We examined how the seven TCI scales and their subscales are correlated with depression severity before and after treatment. We also examined whether changes in personality measures could be attributed to changes in depression severity. METHODS: Two clinical samples of depressed out-patients were recruited for trials to examine predictors of treatment response to antidepressants (N=195) and psychotherapies (N=177). Assessment included the Montgomery-Asberg depression rating scales (MADRS), Hopkins Symptom Checklist (SCL-90) and TCI at baseline and after treatment. RESULTS: After treatment, in both samples, depression severity correlated significantly with HA and negatively with SD. Multiple regression analysis revealed that changes in SD and HA over treatment were related to improvement in depression. In the psychotherapy trial baseline MADRS scores correlated with low SD and high HA. LIMITATIONS: The trial results are applicable to mild-moderately depressed out-patients. CONCLUSIONS: Depression severity influences the total scales and most of the subscale measures of HA and SD. Some personality traits, as measured by the TCI, were not impacted upon by mood. Clinically mood should be taken into account when assessing personality measures of negative affect using the TCI.


Subject(s)
Depressive Disorder, Major/psychology , Personality , Temperament , Adult , Affect/drug effects , Antidepressive Agents, Second-Generation/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use , Cognitive Behavioral Therapy , Female , Fluoxetine/therapeutic use , Humans , Male , Nortriptyline/therapeutic use , Personality/drug effects , Personality Assessment , Psychiatric Status Rating Scales , Psychotherapy , Regression Analysis , Severity of Illness Index
9.
Genetics ; 182(3): 923-6, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19398771

ABSTRACT

beta-Carotene biochemistry is a fundamental process in mammalian biology. Aberrations either through malnutrition or potentially through genetic variation may lead to vitamin A deficiency, which is a substantial public health burden. In addition, understanding the genetic regulation of this process may enable bovine improvement. While many bovine QTL have been reported, few of the causative genes and mutations have been identified. We discovered a QTL for milk beta-carotene and subsequently identified a premature stop codon in bovine beta-carotene oxygenase 2 (BCO2), which also affects serum beta-carotene content. The BCO2 enzyme is thereby identified as a key regulator of beta-carotene metabolism.


Subject(s)
Milk/metabolism , Mutation , Oxygenases/genetics , Amino Acid Sequence , Animals , Base Sequence , Cattle , Chromosomes, Mammalian/genetics , Color , Crosses, Genetic , DNA Mutational Analysis , Female , Genotype , Male , Milk/chemistry , Oxygenases/metabolism , Polymorphism, Single Nucleotide , Quantitative Trait Loci/genetics , beta Carotene/blood , beta Carotene/metabolism
10.
Cell Death Differ ; 16(3): 475-82, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19096393

ABSTRACT

There are two predominant theories for lumen formation in tissue morphogenesis: cavitation driven by cell death, and membrane separation driven by epithelial polarity. To define the mechanism of lumen formation in prostate acini, we examined both theories in several cell lines grown in three-dimensional (3D) Matrigel culture. Lumen formation occurred early in culture and preceded the expression of cell death markers for apoptosis (active caspase 3) and autophagy (LC-3). Active caspase 3 was expressed by very few cells and inhibition of apoptosis did not suppress lumen formation. Despite LC-3 expression in all cells within a spheroid, this was not associated with cell death. However, expression of a prostate-secretory protein coincided with lumen formation and subsequent disruption of polarized fluid movement led to significant inhibition of lumen formation. This work indicates that lumen formation is driven by the polarized movement of fluids and proteins in 3D prostate epithelial models and not by cavitation.


Subject(s)
Cell Death/physiology , Epithelial Cells/cytology , Extracellular Fluid/metabolism , Prostate/cytology , Animals , Biomarkers/metabolism , Cell Culture Techniques , Cell Polarity , Cells, Cultured , Collagen/metabolism , Drug Combinations , Enzyme Inhibitors/metabolism , Epithelial Cells/metabolism , Epithelium/anatomy & histology , Epithelium/metabolism , Humans , Laminin/metabolism , Male , Morphogenesis/physiology , Ouabain/metabolism , Prostate/metabolism , Proteoglycans/metabolism
11.
Acta Neuropsychiatr ; 21(3): 133-40, 2009 Jun.
Article in English | MEDLINE | ID: mdl-26953751

ABSTRACT

BACKGROUND: The protein product of INSIG2 is involved in cholesterol and triglyceride metabolism and homeostasis. Variation at rs7566605 near the gene INSIG2 has been associated with increased BMI. OBJECTIVE: To evaluate the effect of rs7566605/INSIG2 genotype on the ability of valproate-treated bipolar patients (BMI ≥ 25 kg/m2) to lose weight using carnitine supplementation during a 26-week lifestyle intervention study. DESIGN: Forty-eight bipolar patients with clinically significant treatment emergent weight gain were genotyped at the rs7566605 SNP. Participants were randomised to l-carnitine (15 mg/kg/day) or placebo for 26 weeks in conjunction with a moderately energy restricted, low-fat diet. Weight and body fat percent were measured fortnightly. Waist circumference measurements and dual-energy X-ray absorptiometry were used to assess changes in body composition. Obesity-related biomarkers were measured at baseline and 26 weeks. RESULTS: There was a significant interaction between rs7566605/INSIG2 genetic status and treatment with carnitine or placebo. Carnitine had no significant effect on body composition measures in G allele homozygous patients who lost between 0.97 and 2.23 kg of fat. However C allele carriers on average gained 2.28 kg when given a placebo. Carnitine supplementation in this group enabled average weight loss of 2.22 kg of fat (p = 0.01). Approximately half of this mass was in the vital truncal compartment (p = 0.002). Bioinformatic analysis detected that the SNP lies in a highly conserved 336 bp sequence which potentially affects INSIG2 gene expression. CONCLUSIONS: C-carriers at rs7566605, possibly regulating the homeostasis gene INSIG2, lost significantly less weight in this lifestyle intervention study. This effect was reversed by carnitine supplementation.

12.
Biochem J ; 345 Pt 3: 595-601, 2000 Feb 01.
Article in English | MEDLINE | ID: mdl-10642518

ABSTRACT

Two cDNAs encoding the serine protease inhibitor (serpin) neuroserpin were cloned from a rat pituitary cDNA library (rNS-1, 2922 bp; rNS-2, 1599 bp). In situ hybridization histochemistry showed neuroserpin transcripts in the intermediate, anterior and posterior lobes of the pituitary gland and medullary cells in the adrenal gland. Expression of rNS-1 mRNA was restricted to selected cells in the pituitary gland. Analysis of purified secretory-granule fractions from pituitary and adrenal tissues indicated that neuroserpin was found in dense-cored secretory granules. This result suggested that endocrine neuroserpin may regulate intragranular proteases or inhibit enzymes following regulated secretion. To investigate the function of neuroserpin in endocrine tissues we established stable anterior pituitary AtT-20 cell lines expressing neuroserpin. Cells with increased levels of neuroserpin responded by extending neurite-like processes. Extracellular proteolysis by serine protease plasminogen activators has been suggested to regulate neurite outgrowth. As neuroserpin inhibits tissue plasminogen activator (tPA) in vitro, we measured plasminogen-activator levels. Zymographic analysis indicated that AtT-20 cells synthesized and secreted a plasminogen activator identical in size to tPA. A higher-molecular-mass tPA-neuroserpin complex was also observed in AtT-20-cell conditioned culture medium. tPA levels were similar in parent AtT-20 cells and a stable cell line with increased levels of neuroserpin. There was no accumulation of a tPA-neuroserpin complex. Together these results identify endocrine cells as an important source of neuroserpin. Moreover they suggest that neuroserpin is released from dense-cored secretory granules to regulate cell-extracellular matrix interactions through a mechanism that may not directly involve tPA.


Subject(s)
Adrenal Glands/metabolism , Neurites/metabolism , Neuropeptides/genetics , Neuropeptides/metabolism , Pituitary Gland/metabolism , Serpins/genetics , Serpins/metabolism , Amino Acid Sequence , Animals , Cattle , Cell Line , Cloning, Molecular , Cytoplasmic Granules/metabolism , Molecular Sequence Data , Pituitary Gland, Anterior/cytology , Pituitary Gland, Anterior/metabolism , Rats , Serine Proteinase Inhibitors/genetics , Serine Proteinase Inhibitors/metabolism , Subcellular Fractions , Tissue Plasminogen Activator/antagonists & inhibitors , Tissue Plasminogen Activator/metabolism , Neuroserpin
13.
Haemophilia ; 1(2): 140-4, 1995 Apr.
Article in English | MEDLINE | ID: mdl-27214325

ABSTRACT

The case records of 13 patients (24 pregnancies) with von Willebrand's disease (vWD) were studies rettospectively. The overall incidence of primary and secondary post-partum haemorrhage (PPH) was 15.8% and 25% respectively, all primary PPH occurring in tyre 2 discase (3/14 deliveries, 21.4%). The risk of primary PPH in type 2 patients who did not receive prophylactic factor VIII was 37.5% (3/8 deliveries). Factor VIII coagulant activity (VIII:C) and von Willebrand factor antigen (vWF:Ag) rose above bascline values by a factor of at least 1.5 during the pregnancy in most case. More severely affected patients were less likely to benefit significatntly. A baseline VIII:C of <15 iu/dl (4/14 cases) was predictive of a third trimester level of <15 iu/dl. Improvements in the von Willebrand factor activity were less marked. The baseline von Willebrand factor activity was <15 iu/dl in all patients with serial data, none of whom achieved a third-trimester von Willebrand factor activity of >50 iu/dl. The bleeding times were unaltered significantly in all but one of the cases, reflecting a general failure of the primary haemostatic defect to improve with pregnancy. The findings demonstrate that coagulation parameters do not universally improve in pregnancy in vWD, especially when preconception levels are low. The risk of primary PPH is generally higher in type 2 diseases. The level of factor VIII:C is not a good predictor of the risk of primary PPH in type 2 patients. Secondary PPH is a significatnt risk in both type 1 and type 2 patients.

16.
Ultrasound Obstet Gynecol ; 4(1): 76-7, 1994 Jan 01.
Article in English | MEDLINE | ID: mdl-12797231

ABSTRACT

A case is described where transvaginal color Doppler was used to demonstrate upward external iliac vein extension of thrombus at 26 weeks' gestation. Normally, transabdominal color Doppler can visualize the iliac vessels, but in advanced pregnancy the uterus obstructs the view. This technique is useful in determining of there is a 'high' deep vein thrombosis in pregnancy, and may also prove useful in the obese patient.

17.
Br Heart J ; 70(6): 544-5, 1993 Dec.
Article in English | MEDLINE | ID: mdl-8280520

ABSTRACT

The outcome of unrelieved severe symptomatic aortic stenosis in pregnancy is poor. Though the valve lesion can be corrected surgically before delivery at a low risk to the mother, cardiopulmonary bypass during pregnancy carries a high risk to the fetus. Two patients in the second trimester of pregnancy were successfully managed with balloon dilatation of the aortic valve. Both delivered healthy infants and were well a year later. Balloon dilatation of the aortic valve is a useful palliative procedure in the management of pregnant women with severe aortic stenosis.


Subject(s)
Aortic Valve Stenosis/therapy , Catheterization , Pregnancy Complications, Cardiovascular/therapy , Adult , Aortic Valve/diagnostic imaging , Aortic Valve Stenosis/diagnostic imaging , Echocardiography, Doppler , Female , Humans , Pregnancy , Pregnancy Trimester, Second
18.
Br J Hosp Med ; 49(10): 739-42, 1993.
Article in English | MEDLINE | ID: mdl-8324597
20.
BMJ ; 305(6849): 369, 1992 Aug 08.
Article in English | MEDLINE | ID: mdl-1392911
SELECTION OF CITATIONS
SEARCH DETAIL
...